Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Equivalents Common Equity Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Repurchased Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Lisata Therapeutics (LSTA) Shares Outstanding (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Shares Outstanding readings, the most recent being $8.8 million for Q4 2025.

For the quarter ending Q4 2025, Shares Outstanding rose 5.05% year-over-year to $8.8 million, compared with a TTM value of $8.8 million through Dec 2025, up 5.05%, and an annual FY2025 reading of $8.8 million, up 5.05% over the prior year.
Shares Outstanding hit $8.8 million in Q4 2025 for Lisata Therapeutics, up from $8.8 million in the prior quarter.
The five-year high for Shares Outstanding was $8.8 million in Q4 2025, with the low at $8.0 million in Q1 2023.
Median Shares Outstanding over the past 3 years was $8.3 million (2024), compared with a mean of $8.4 million.
The sharpest move saw Shares Outstanding rose 2.21% in 2024, then grew 5.24% in 2025.
Year by year, Shares Outstanding stood at $8.2 million in 2023, then rose by 3.17% to $8.4 million in 2024, then grew by 5.05% to $8.8 million in 2025.
According to Business Quant data, Shares Outstanding over the past three periods came in at $8.8 million, $8.8 million, and $8.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.